Exane Derivatives’s Quest Diagnostics DGX Stock Holding History

Exane Derivatives’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$989K	Buy	7,435 +636	+9%	+$86.7K	0.57%	42
2022 Q1	$930K	Buy	6,799 +1,019	+18%	+$142K	0.26%	102
2021 Q4	$1,000K	Sell	5,780 -214	-4%	-$32.6K	0.24%	93
2021 Q3	$871K	Buy	5,994 +440	+8%	+$64.4K	0.21%	101
2021 Q2	$750K	Sell	5,554 -356	-6%	-$46.6K	0.17%	116
2021 Q1	$758K	Sell	5,910 -1,713	-22%	-$211K	0.22%	103
2020 Q4	$908K	Buy	+7,623	New	+$929K	0.27%	96
2018 Q4	–	Sell	-1	Closed	-$108	–	695
2018 Q3	$108	Hold	1	–	–	﹤0.01%	618
2018 Q2	$111	Hold	1	–	–	﹤0.01%	610
2018 Q1	$99	Hold	1	–	–	﹤0.01%	552
2017 Q4	$98	Sell	1 -1	-50%	-$95	﹤0.01%	545
2017 Q3	$187	Sell	2 -14	-88%	-$1.49K	﹤0.01%	490
2017 Q2	$1.78K	Buy	+16	New	+$1.69K	﹤0.01%	454

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Exane Derivatives's DGX Position: Q2 2022 in Review

Exane Derivatives increased its Quest Diagnostics (DGX) stake by 9.4% in Q2 2022, buying an estimated $86.7K and bringing the position to 7,435 shares worth $989K. The position accounts for 0.57% of the portfolio, ranked #42.

Exane Derivatives first reported a position in DGX in Q2 2017 and has held it in 13 quarters since. The position peaked at $1,000K in Q4 2021. 852 funds tracked by Wall St. Rank hold DGX as of Q2 2022.

Exane Derivatives held 7,435 shares of Quest Diagnostics worth $989K as of Q2 2022.
Exane Derivatives bought 636 Quest Diagnostics shares in Q2 2022, an estimated $86.7K.
Quest Diagnostics made up 0.57% of Exane Derivatives's portfolio in Q2 2022, its #42 holding.
Exane Derivatives first reported a position in Quest Diagnostics in Q2 2017 and has held it in 13 quarters since.
Exane Derivatives's Quest Diagnostics position peaked at $1,000K in Q4 2021.
852 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.